Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosamax esophageal side effects more serious than seen in clinical trials -- Merck letter to doctors.

Executive Summary

MERCK FOSAMAX ESOPHAGEAL SIDE EFFECTS MORE SEVERE than previously seen in clinical trials, the company told health care professionals in a March 18 letter. The letter states that "since market introduction of the product, some [esophageal] side effects have been of greater severity than we observed in our controlled clinical trials. It is clear from the case reports...that Fosamax can be irritating to the esophagus but that careful adherence to the dosing instructions can reduce the potential for these side effects." Merck sent the letter to 150,000 physicians; the company sent another 50,000 letters to pharmacists March 25.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel